The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse

Am J Hematol. 2023 Feb;98(2):E38-E40. doi: 10.1002/ajh.26787. Epub 2022 Dec 4.

Vaibhav Agrawal^{1

2}, Amandeep Salhotra^{1

2}, Joo Song³, Zhaohui Gu^{3

4}, Anthony S Stein^{1

2}, Guido Marcucci^{1

2}, Stephen J Forman^{1

2}, Vinod Pullarkat^{1

2}, Ibrahim Aldoss^{1

2}

¹ Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope National Medical Center, Duarte, California, USA.
² Department of Pathology, City of Hope National Medical Center, Duarte, California, USA.
³ Department of Computational and Quantitative Medicine, Beckman Research Institute at City of Hope, Duarte, California, USA.
⁴ Department of Systems Biology, Beckman Research Institute at City of Hope, Duarte, California, USA.

No abstract available

Publication types